Biotech Values

[DewDiligence]

Bausch & Lomb drops AMD / DME program:

That’s one fewer competitor to worry about. It’s been known for some time that Bausch’s AMD / DME program was in trouble, but the comments in the company’s 1/29/04 PR made it official, and the decision was confirmed by CEO Ron Zarella on Bausch’s 4Q03 CC:

>>
“I wanted to briefly comment on our decision regarding the current generation of Retisert implant with Fluocinolone Acetonide. We have decided to focus our ongoing development of this technology on the posterior uveitis indication.

After a review of the overall [Retisert] program, we determined that further development of the DME and AMD indications isn’t warranted. Treatments for diseases of the posterior segment, including DME and AMD, remain an important focus of our ongoing development efforts. We’ll continue to pursue other programs to address these conditions, including different compounds, different delivery mechanisms, or both.”
<<